While MedImmune Inc. awaits word from the FDA on the supplemental biologics license application for its flu vaccine and seeks ways to pump sales of Synagis, the firm signed a potential $500 million deal with Infinity Pharmaceuticals Inc. focused on small-molecule cancer drugs targeting heat-shock protein 90 (Hsp90) and the Hedgehog cell-signaling pathway. (BioWorld Today)

Public shell company Orthodontix Inc. is gaining a Phase III-ready drug for Gaucher's disease along with a plant-cell bioreactor for making proteins in its merger with Israeli firm Protalix Ltd. (BioWorld Today)

The letter from a major shareholder of Nabi Pharmaceuticals Inc., attacking CEO Thomas McLain for the company's "abysmal" performance and "bargain-basement stock price," sent Nabi's shares up about 5 percent on the day it was made public last week, but the story may not be over. (BioWorld Today)